Leveraging RWE to grow your business with a high-multiple ROI
Market access is a key area for any life sciences company, and developing an evidence generation strategy is paramount for market access success. To help achieve market access success, real world data (RWD) is able to provide direct insight into the daily application of a drug or medical device. Once RWD is gathered, real world evidence (RWE) can be developed to publish your value proposition in the peer-reviewed literature and facilitate payer coverage and key opinion leader (KOL)/provider adoption. When used in an evidence generation strategy, RWE can effectively communicate product value to your desired stakeholders.
Join Baker Tilly for an informative discussion that will examine how life science companies can utilize RWE to demonstrate clinical and economic value and improve your market access strategy. Our team will discuss:
There are no prerequisites for this webinar, and advance preparation is not required. There is no cost to attend this webinar.
A certificate of completion will be emailed to you four to six weeks after the event.
For more information regarding administrative policies such as complaint and refund, please contact our offices at +1 (608) 240 2522.
Baker Tilly US, LLP is registered with the National Association of State Boards of Accountancy (NASBA) as a sponsor of continuing professional education on the National Registry of CPE Sponsors. State boards of accountancy have final authority on the acceptance of individual courses for CPE credit. Complaints regarding registered sponsors may be submitted to the National Registry of CPE Sponsors through its website: learningmarket.org.